Cathie Wood Loads Up $4.6M In Crowdstrike After Q3 Loss Widens, Offloads This Audio Streaming Stock

Cathie Wood-led ARK Investment Management bought over 39,000 shares of cybersecurity technology company Crowdstrike Holdings Inc (NASDAQ: 

Cathie Wood-led ARK Investment Management bought over 39,000 shares of cybersecurity technology company Crowdstrike Holdings Inc (NASDAQ: CRWD) at an estimated valuation of over $4.6 million on Wednesday.

The purchase was done via the ARK Next Generation Internet ETF (NYSE: ARKW). Crowdstrike is the 26th largest holding of the fund, with a weight of 1.04%. Zoom Video Communications Inc (NASDAQ: ZM), Roku Inc (NASDAQ: ROKU) and Tesla Inc (NASDAQ: TSLA) are the top three holdings of the fund.

Also Read: How To Invest In Startups

Earnings Impact: On Tuesday, the company reported its earnings, registering a bigger net loss during the third quarter. GAAP net loss attributable to CrowdStrike stood at $55 million, compared to $50.5 million in the third quarter of fiscal 2022.

The company said that annual recurring revenue (ARR) increased 54% year-over-year and grew to $2.34 billion as of October 31, 2022, of which $198.1 million was net new ARR added in the quarter. 

George Kurtz, CrowdStrike’s co-founder and CEO, said total net new ARR was below expectations as increased macroeconomic headwinds elongated sales cycles with smaller customers and caused some larger customers to pursue multi-phase subscription start dates.

Shares of the company fell over 14% on Wednesday despite a Wall Street rally led by Federal Reserve Chair Jerome Powell’s comments on the potential slowing of the rate hike pace.

Major Sale: ARK sold over 57,000 shares of Spotify Technology SA (NYSE: SPOT) at an estimated valuation of over $4.5 million. Spotify shares closed over 5% on Wednesday.

Read Next: Larry Summers Says Hard To See Wage Inflation ‘Substantially’ Subsiding With Huge Labor Supply-Demand Imbalance

 

 

Total
0
Shares
Related Posts
Read More

Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co’s Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share

Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the

DRMA